Canagliflozin hemihydrate is a sodium-glucose cotransporter-2 (SGLT2) inhibitor indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control. By inhibiting renal glucose… Read more
Canagliflozin hemihydrate is a sodium-glucose cotransporter-2 (SGLT2) inhibitor indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control. By inhibiting renal glucose reabsorption, this medication reduces blood glucose levels independently of insulin secretion. Laboratories require high-quality reference standards for canagliflozin hemihydrate to support rigorous analytical testing, including impurity profiling and method validation. This category encompasses the active pharmaceutical ingredient alongside its pharmacopeial and non-pharmacopeial impurities, which are critical for monitoring drug substance purity during development and manufacturing. Additionally, stable isotope-labeled compounds are available to serve as internal standards for mass spectrometry-based assays, ensuring accurate quantification and consistent quality control within pharmaceutical research.